Investment to Support Technology Roll-Out

Biomanufacturing company Univercells SA, (Gosselies, Belgium) has announced the successful closing of a €3 million ($3.56M) increase in a Series-A equity financing round, led by private investors from Europe and the US.

The capital injection will help enable the commercial introduction of the company’s viral micro-facility, with a first technology transfer anticipated for Q4 2018 within the framework of the Bill & Melinda Gates Foundation-supported program; it will also benefit the company’s recombinant platform development, both of which are aimed at providing a sufficient supply of high-quality biologics at an affordable price.

“We are very proud of this funding round and thankful for this wealth of support,” commented Hugues Bultot, co-founder and CEO of Univercells. “This successful capital increase is a real recognition of the work achieved so far, the innovative technology being developed and the clear expectations and roadmap set. It is highly encouraging to have seasoned industry experts demonstrate such tremendous confidence in Univercells, its ability to transform the industry with their willingness to contribute to our mission.”